Eupraxia Pharmaceuticals Inc. (EPRX)

NASDAQ: EPRX · IEX Real-Time Price · USD
2.770
-0.040 (-1.42%)
At close: Jul 15, 2024, 3:44 PM
2.640
-0.130 (-4.69%)
After-hours: Jul 15, 2024, 6:52 PM EDT
-1.42%
Market Cap 95.47M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 35.62M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,425
Open 2.870
Previous Close 2.810
Day's Range 2.630 - 2.870
52-Week Range 2.402 - 3.500
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About EPRX

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign struc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 29
Stock Exchange NASDAQ
Ticker Symbol EPRX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

VICTORIA, BC , July 8, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Dif...

7 days ago - PRNewsWire

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

Osteoarthritis ("OA") is the leading cause of disability in older adults. The U.S. Centers for Disease Control and Prevention estimates that knee OA affects more than 30 million people in the U.S. alo...

12 days ago - PRNewsWire

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

VICTORIA, BC , June 6, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Dif...

5 weeks ago - PRNewsWire

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

VICTORIA, BC, June 5, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diff...

5 weeks ago - PRNewsWire

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eight of nine patients responding to the treatment, plus the encouraging safety data observed in the RESOLVE Phase 1b/2a trial of EP-104GI, provided the catalyst for the trial expansion Early low-dose...

7 weeks ago - PRNewsWire

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

VICTORIA, BC , May 22, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Dif...

7 weeks ago - PRNewsWire

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Trial's first and second cohorts maintaining signs of potential efficacy out to 24 weeks Data from  the second cohort showed improvements in eosinophil counts and histological scores out to 12 weeks s...

7 weeks ago - PRNewsWire

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

VICTORIA, BC , May 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Dif...

2 months ago - PRNewsWire

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Eupraxia common shares now listed on the Nasdaq Capital Market ("Nasdaq") under the symbol "EPRX" Additional data from RESOLVE study evaluating EP-104GI for the treatment of eosinophilic esophagitis (...

2 months ago - PRNewsWire

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

--Advisory Board to Provide Guidance for Company's Eosinophilic Esophagitis Clinical Program--  VICTORIA, BC , May 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (T...

2 months ago - PRNewsWire

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

VICTORIA, BC , April 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary D...

3 months ago - PRNewsWire

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

VICTORIA, BC , April 8, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary D...

3 months ago - PRNewsWire

Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today

VICTORIA, BC , April 5, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary D...

3 months ago - PRNewsWire

Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

Company's Listing Application Approved by Nasdaq VICTORIA, BC , April 3, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage b...

3 months ago - PRNewsWire

Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results

VICTORIA, BC , April 1, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ tech...

3 months ago - PRNewsWire